Good morning,
I've been researching the officers and the interim CEO from the latest financial of April 24. The interim CEO is MS. Caren Currier. She has an interesting bio and much of her standing within the corporate world is in Biotechnology.
Her bio: Currier is currently the Chief Financial Officer & Director at One World Universe, Inc. and the Finance Manager at China Liaoning Dingxu Ecological Agriculture Development, Inc. Previously, she served as the President, CEO, CFO, Secretary & Treasurer at KAT Exploration, Inc. from 2021 to 2023, the Chief Financial Officer & Director at Zalemark Holding Co., Inc. from 2014 to 2017, and the Chief Financial Officer at FCCC, Inc. in 2021.
Ms. Currier's education includes an undergraduate degree from Mt.
San Antonio College Foundation.
Ms. Currier position as Finance Director is with China Liaoning Dingxu Ecological Agriculture Development, Inc., through its subsidiaries, grows, produces, markets, and sells agriculture products in the People’s Republic of China. The company offers fresh mushrooms, such as oyster, king oyster, shiitake, king trumpet, and button mushrooms; dried mushrooms, including eryngii, white, jade, and white king oyster mushrooms, as well as ganoderma mushrooms; and mushroom seeds. It sells its fresh and dried mushrooms to stores that sell directly to individual customers; and mushroom seeds to farmers in the form of stick shaped containers filled with fertilizers, as well as bottles of mushroom seeds. The company was formerly known as Hazlo! Technologies, Inc. and changed its name to China Liaoning Dingxu Ecological Agriculture Development, Inc. in October 2011. China Liaoning Dingxu Ecological Agriculture Development, Inc. was founded in 2009 and is based in West Palm Beach, Florida.
This company trades on the OTC as CLAD price 1.00$
As Due Diligence Virtuoso mentioned the bringing onboard Mr. Jeslie Chui and here is his BIO.
For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few.
In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.
Mr. Chui will work closely with our recently launched distributor Mango Wellness, in Thailand, and two distributors scheduled to be operational in the next few months in Malaysia and Singapore. He will help expedite the start-up process there, and working along with these distributors, identify other areas of expansion in the region for growth. In this new role he will also be a corporate liaison as part of our new Collaborative Partnership with Semacare and assist, as needed, in our ongoing efforts to complete the regulatory certification of our myCam device with the National Medical Products Administration (NMPA) in China.
“We welcome Jeslie Chui to our company. As Director of Business Development, Jeslie will be instrumental in helping to promote awareness and increase corporate recognition of CB Scientific Inc. in the Asia Pacific region. Through his efforts there, we look forward to expanding our outreach by providing state-of-the-art Remote Cardiac Monitoring through our my-Cardia products and services to help reduce the impact of heart disease in this area of the world through early detection improving the quality of life for patients,” said Charles Martin, President and CEO of CB Scientific, Inc. in a statement.
CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
The interesting aspect of this is becoming very promising. We do know the company increased the A/S to 50B and O/S to 44B. There really are only 2 reasons for this, one being the protection against Greenmailing when the merger is complete. The other reason is in what degree will the new entity entail with respect to assets. See the increase in a R/M candidate is very unusual since most share structure design is to lower, but in this case, we have an increase. This makes me think that the acquired candidate may have very promising assets whereas the company put in this protection mechanism.
I'm on the mindset that the merger will be in the area of medical or biotechnology and the adjustment of the huge share structure could involve valuable assets.
I'm becoming very interested and excited in this company on the pending merger.
Have a good day.
varok
